Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Ipatasertib from the National Medical Products Administration, indicating a significant regulatory approval for the company [1] Group 1: Product Information - Ipatasertib is a reversible non-competitive inhibitor of aldose reductase, selectively inhibiting the enzyme [1] - Clinical studies have shown that Ipatasertib can inhibit the accumulation of sorbitol in red blood cells of patients with diabetic peripheral neuropathy, improving subjective symptoms and neurological dysfunction compared to the control group [1]

Group 1 - Kanghong Pharmaceutical recently received a drug registration certificate from the National Medical Products Administration for Ipatasertib tablets, indicated for diabetic neuropathy [1] - Luxi Chemical is advancing resource integration and optimizing its management structure, planning to absorb and merge its wholly-owned subsidiary, Shandong Liaocheng Luxi Chemical Second Fertilizer Co., Ltd. [1] - Tongling Nonferrous Metals has proposed a profit distribution plan for the first half of 2025, intending to distribute a cash dividend of 0.5 yuan (including tax) for every 10 shares [1] Group 2 - Haitai Technology's "Haitai Convertible Bonds" have their last conversion day on September 29, with only half a trading day left after the morning close. Investors who do not convert in time may face losses [1] - Songyuan Safety has only half a trading day left for the conversion of "Songyuan Convertible Bonds," which will stop converting after the afternoon trading session on September 29. Remaining convertible bonds will be forcibly redeemed at a price of 100.07 yuan per bond, potentially leading to significant investment losses for investors [1]

Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Ipatasertib tablets from the National Medical Products Administration, indicating approval for the treatment of diabetic neuropathy [1] Company Summary - Kanghong Pharmaceutical (002773.SZ) has recently announced the approval of Ipatasertib tablets, which are specifically indicated for diabetic neuropathy [1]

Group 1 - The core point of the article is that Kanghong Pharmaceutical has received the drug registration certificate for Ipatasertib from the National Medical Products Administration, indicating regulatory approval for the drug [1] - The approved indication for Ipatasertib is diabetic neuropathy, which highlights the company's focus on addressing complications related to diabetes [1]

Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Ipatasertib from the National Medical Products Administration, indicating a significant advancement in its product pipeline for treating diabetic neuropathy [1] Company Summary - Kanghong Pharmaceutical announced the receipt of the drug registration certificate for Ipatasertib, which is intended for the treatment of diabetic neuropathy [1]

Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Ipatasertib tablets, indicating a significant regulatory approval for a new treatment for diabetic neuropathy [1][2]. Group 1: Drug Information - Drug Name: Ipatasertib Tablets [1] - Dosage Form: Tablet [1] - Specification: 50mg [1] - Indication: Diabetic neuropathy [1] Group 2: Regulatory Approval - Registration Classification: Chemical Drug Class 3 [2] - Approval Number: National Drug Approval Code H20255572 [2] - Approval Conclusion: The drug meets the requirements for registration as per the Drug Administration Law of the People's Republic of China [2]. Group 3: Mechanism and Clinical Research - Ipatasertib is a reversible non-competitive inhibitor of aldose reductase, selectively inhibiting the enzyme [2]. - Clinical studies have shown that Ipatasertib can inhibit the accumulation of sorbitol in red blood cells of patients with diabetic peripheral neuropathy, improving subjective symptoms and neurological dysfunction compared to the control group [2].

关于公司收到药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 证券代码：002773 证券简称：康弘药业 公告编号：2025-052 成都康弘药业集团股份有限公司 1 / 2 二、产品简介 成都康弘药业集团股份有限公司（以下简称"公司"）于近日收 到国家药品监督管理局签发的依帕司他片的《药品注册证书》（证书 编号：2025S02992），批准注册。现将相关情况公告如下： 一、药品基本信息 药品名称：依帕司他片 剂型：片剂 规格：50mg 适应症：糖尿病性神经病变。 注册分类：化学药品 3 类 批准文号：国药准字 H20255572 审批结论：根据《中华人民共和国药品管理法》及有关规定，经 审查，本品符合药品注册的有关要求，批准注册，发 给药品注册证书。 依帕司他是一种可逆性的醛糖还原酶非竞争性抑制剂，对醛糖还 原酶具有选择性抑制作用。临床研究显示，依帕司他能抑制糖尿病性 外周神经病变患者红细胞中山梨醇的积累，与对照组比较能改善患者 的自觉症状和神经功能障碍。 三、对公司的影响 本次依帕司他片获批上市，丰富了公司的产品管线。 由于医药产品的生产 ...

Core Insights - Kanghong Pharmaceutical (002773) reported that as of September 19, 2025, the number of shareholders is 24,909 [1] Company Summary - The company has engaged with investors through an interactive platform, providing updates on shareholder statistics [1]

Market Overview - The biopharmaceutical sector experienced a decline of 0.21% on September 25, with Nossland leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Aopu Mai (688293) with a closing price of 62.85, up 7.42% and a trading volume of 30,600 [1] - Rongchang Biotech (688331) closed at 108.50, up 3.43% with a trading volume of 89,200 [1] - Baipusais (301080) closed at 62.16, up 3.43% with a trading volume of 43,500 [1] - Major decliners included: - Nossland (430047) closed at 22.99, down 3.69% with a trading volume of 57,000 [2] - Wufan Biotech (301393) closed at 53.12, down 3.42% with a trading volume of 24,600 [2] - Kexing Pharmaceutical (688136) closed at 38.75, down 3.34% with a trading volume of 53,500 [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 207 million yuan from institutional investors, while retail investors contributed a net inflow of 45.07 million yuan [2] - Notable capital flows included: - Rongchang Biotech (688331) with a net inflow of 1.021 billion yuan from institutional investors [3] - Junshi Biosciences (688180) with a net inflow of 35.36 million yuan from institutional investors [3] - Aopu Mai (688293) with a net inflow of 9.41 million yuan from institutional investors [3]

Core Viewpoint - Kanghong Pharmaceutical's stock has shown significant volatility, with a year-to-date increase of 96.63% but a recent decline in the last five and twenty trading days [1][2]. Group 1: Stock Performance - As of September 24, Kanghong Pharmaceutical's stock price was 37.36 CNY per share, with a market capitalization of 34.42 billion CNY [1]. - The stock experienced a net inflow of 5.30 million CNY from main funds, with large orders accounting for 13.33% of purchases [1]. - The stock has seen a 5.70% decline over the last five trading days and an 8.27% decline over the last twenty trading days [1]. Group 2: Financial Performance - For the first half of 2025, Kanghong Pharmaceutical reported a revenue of 2.45 billion CNY, representing a year-on-year growth of 6.95%, and a net profit of 730 million CNY, up 5.41% year-on-year [2]. - The company has distributed a total of 2.04 billion CNY in dividends since its A-share listing, with 1.04 billion CNY distributed in the last three years [3]. Group 3: Shareholder Information - As of September 10, the number of shareholders for Kanghong Pharmaceutical was 24,700, a decrease of 1.19% from the previous period [2]. - The average number of circulating shares per shareholder increased by 1.21% to 27,778 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and several mutual funds, with notable changes in their holdings [3].